Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > I am a bit bipolar

<< Previous

Bullboard Posts

Next >>

Comment by JayjayUSA12007on Jun 24, 2021 1:36am

148 Views

Post# 33439950

RE:RE:RE:RE:RE:RE:I am a bit bipolar

"...If 1902 succeeeds then the whole platform increases in value. You don't need to double or triple your clinical costs by adding a 2nd or 3rd molecule in order to see massive gains...."

Excellent point, Qwerty22 ! Once SORT is proven to be the "key" to enter cancer cells, mix and match other molecules against other types of cancer would become a new paradigm for cancer treatment.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?